8% CONVERTIBLE PROMISSORY NOTE DUE NOVEMBER 30, 2017Premier Biomedical Inc • August 21st, 2017 • Biological products, (no disgnostic substances) • New York
THIS 8% CONVERTIBLE PROMISSORY NOTE is one of three duly authorized and validly issued 8% Convertible Promissory Notes of Premier Biomedical Inc. (the “Company”), having its principal place of business at P.O. Box 31374, El Paso, TX 79930, designated as its 8% Convertible Notes due November 30, 2017 (this Note, the “Note” and, collectively with the other Notes of such series, the “Notes”).
AMENDMENT NO. 1 SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 21st, 2017 • Premier Biomedical Inc • Biological products, (no disgnostic substances)
This First Amendment to the Securities Purchase Agreement (this “Amendment”) is entered into on August 8, 2017 between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser” and collectively with all other purchasers in the same offering, the “Purchasers”). Each of the Purchasers and the Company may be referred to herein as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 21st, 2017 • Premier Biomedical Inc • Biological products, (no disgnostic substances)
This First Amendment to the Registration Rights Agreement (this “Amendment”) is entered into on August 4, 2017 between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (including its successors and assigns, the “Purchaser” and collectively with all other purchasers in the same offering, the “Purchasers”). Each of the Purchasers and the Company may be referred to herein as a “Party” and collectively as the “Parties.”
EXCHANGE AGREEMENTExchange Agreement • August 21st, 2017 • Premier Biomedical Inc • Biological products, (no disgnostic substances) • New York
This Exchange Agreement (this “Agreement”) is entered into on August 8, 2017 by and between Premier Biomedical, Inc., a Nevada corporation (the “Company”) and [•] (the “Shareholder”). Any capitalized terms not defined herein shall have the meaning given to such term in the Securities Purchase Agreement.
